In hepatocellular carcinoma, UBE2T activates this pathway through several mechanisms, including downregulating Mule (an E3 ubiquitin ligase responsible for β-catenin degradation), promoting β-catenin translocation, activating the MAPK/ERK signaling pathway, and interacting synergistically with other signaling pathways [44,45]. The gene discussed is UBE2T; the disease is hepatocellular carcinoma.